Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sven Rose

Diagnostic Radiology Santa Fe, NM Medical Doctor

NPI 1841257409 CMS profile 83910

490A W Zia Rd, Santa Fe, NM 87505

Open in the dashboard

General payments

$4,487

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sven Rose of Santa Fe, NM is reported in the CMS Open Payments database as having received $4,487 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75 2
2024 General $649 7
2023 General $1,012 16
2022 General $1,457 25
2021 General $289 6
2020 General $132 5
2019 General $874 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sven Rose
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Sven Rose were reported at $75. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Sven Rose Diagnostic Radiology median Middle half National median
2019 $874 $108 $29–$318 $163
2020 $132 $65 $21–$252 $114
2021 $289 $92 $24–$292 $132
2022 $1,457 $104 $29–$294 $149
2023 $1,012 $110 $29–$337 $160
2024 $649 $113 $30–$356 $164
2025 $75 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $981 16 payments
  2. Philips Electronics North America Corporation $859 12 payments
  3. Abbott Laboratories $613 7 payments
  4. Medtronic, Inc. $450 4 payments
  5. Cook Medical LLC $407 9 payments
  6. Medtronic USA, Inc. $216 6 payments
  7. Boston Scientific Corporation $170 6 payments
  8. AngioDynamics, Inc. $147 3 payments
  9. Terumo Medical Corporation $111 4 payments
  10. Siemens Medical Solutions USA, Inc. $93 1 payment
  11. Other $442 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,487 85 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $914 15 payments
  2. CT THROMBECTOMY SYSTEM KIT $914 15 payments
  3. Abre $294 2 payments
  4. (4067) Tack Endo Sys BTK $218 2 payments
  5. KYPHON Balloon Kyphoplasty $216 6 payments
  6. Cook Medical Zilver PTX $183 2 payments
  7. Diamondback Peripheral $150 1 payment
  8. IGT D Peripheral $149 2 payments
  9. HawkOne $146 1 payment
  10. (6536) Phoenix $137 1 payment
  11. Other $2,283 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Diagnostic Radiology: 24

Drug cost

$70

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 11 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 255 billing codes

Paid by Medicare

$381,208

Of which drugs: $1,523

Medicare patients

1,821

Average age 74

Services billed

16,368

1,101 women, 720 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 60%
Diabetes 32%
Ischemic heart disease 27%
Chronic kidney disease 26%
Depression 23%
COPD 21%
Cancer 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 139 12,813 $1,352
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 45 48 $50
Injection, cefazolin sodium, 500 mg J0690 Office 23 44 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record